Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
952.74
-1.43 (-0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
August 19, 2024
Impediments to growth are melting away while new opportunities begin to rise.
Via
The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
August 18, 2024
Eli Lilly has a lot going for it.
Via
The Motley Fool
Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock
August 18, 2024
There's no stopping this incredible pharmaceutical stock.
Via
The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
August 18, 2024
Should Novo Nordisk and Eli Lilly investors be worried about Roche?
Via
The Motley Fool
3 Companies Reporting Remarkable Results: Walmart, Eli Lilly, Cardinal Health
August 17, 2024
Several companies have stolen the spotlight throughout the earnings period, including Walmart, Cardinal Health, and Eli Lilly. All three posted robust results and upped guidance, as shares of each...
Via
Talk Markets
Is Madrigal Pharmaceuticals Stock a Buy?
August 17, 2024
The biotech could be worth a lot more in 10 years.
Via
The Motley Fool
Eli Lilly Unusual Options Activity For August 15
August 15, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years
August 13, 2024
Via
Benzinga
3 Fantastic Growth Stocks to Buy in August
August 17, 2024
These stocks should keep up their winning ways.
Via
The Motley Fool
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
August 17, 2024
Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future.
Via
The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
August 16, 2024
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare...
Via
Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while...
Via
Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
August 16, 2024
A small telemedicine company just entered the weight loss race.
Via
The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
There are a number of pharmaceutical companies looking to make waves in the weight loss market.
Via
The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
The unveiled prices follow months of back-and-forth negotiation between the government and the companies.
Via
Investor's Business Daily
3 Biotech Stocks to Buy on the Dip: August 2024
August 15, 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.
Via
InvestorPlace
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
August 14, 2024
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
August 14, 2024
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection...
Via
Benzinga
Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?
August 14, 2024
How much upside could this juggernaut stock possibly have left?
Via
The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
August 13, 2024
Eli Lilly stock and Novo Nordisk kicked off the vanity trade, but the "me-conomy" trend is extending to other industries as well.
Via
Investor's Business Daily
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
August 13, 2024
Investing based on the segment's long-term prospects is likely to be very lucrative.
Via
The Motley Fool
3 Stocks on the Rise After Stellar Q2 Earnings Results
August 13, 2024
These three companies are earnings winners with impressive revenue and profit numbers. They will continue to shine throughout 2024.
Via
InvestorPlace
VOO Vs. VTI: Here Are The Key Differences Between Vanguard US Stock Market ETFs Investors Should Know
August 13, 2024
A look at the differences and past performance of the VOO and VTI ETFs and how they compare to the SPY ETF.
Via
Benzinga
Topics
ETFs
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
August 13, 2024
A company's investments can easily ruin the plans of its competitors.
Via
The Motley Fool
Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run
August 13, 2024
Many more quarters like Lilly's stellar second quarter could be on the way.
Via
The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
August 12, 2024
GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer risk, particularly for cancers linked to obesity. New research highlights...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
August 12, 2024
Via
Benzinga
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
August 12, 2024
There isn't much to suggest these businesses are actually vulnerable.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.